A

Avantor

Global provider of high-purity lab materials

Biopharma Production Specialist

Full-TimeUpdated on 10/24/2026
No salary listed
Senior
Bachelor's
Remote in Spain+2 moreMore locations: Llinars del Vallès, Barcelona, Spain | Amsterdam, Netherlands
RemoteRegular travel throughout Europe is required.
Sales & Account ManagementField Sales, Account Management

About the job

Requirements
  • A bachelor's degree (BSc/BA) in Chemistry, Life Sciences, Chemical Engineering, Genetic Engineering, or another relevant life sciences discipline.
  • A minimum of 5 years of sales experience within the biopharmaceutical manufacturing industry or a related life sciences sector.
  • A proven track record of achieving and exceeding sales targets.
  • Strong knowledge of Microsoft Office applications, particularly PowerPoint, Excel, and Word.
  • Ability to recognize the need for change and implement appropriate strategies to facilitate it.
  • Ability to work effectively in a fast-changing environment and perform well under pressure.
  • Ability to manage multiple priorities simultaneously.
  • A valid driver's license.
  • Business-fluent English.
  • Ability to travel regularly throughout Europe.
Responsibilities
  • Increase regional awareness of Avantor’s value proposition as a manufacturer and supplier of bioprocess chemicals, sera, single-use technologies, buffer management solutions, and bioprocess systems.
  • Promote products and services that support the manufacturing of monoclonal antibodies, vaccines, cell and gene therapies, peptides, and other biologics.
  • Work closely with Technical Applications Specialist teams to engage customers in value-added programs and technical projects.
  • Build and maintain long-term business relationships with customers to strengthen loyalty and drive sustainable growth.
  • Execute company strategies to achieve sales growth across the assigned region.
  • Champion internal alignment among key stakeholders to ensure customer opportunities are managed and executed efficiently.
  • Identify and lead the development of new custom manufacturing opportunities.
  • Drive growth in strategic product areas including single-use assemblies, fluid handling systems, mixing technologies, and buffer management platforms.
  • Generate growth opportunities in the Netherlands and Southern European region with existing and new customers.
  • Develop sustainable and profitable partnerships with biopharmaceutical customers, particularly those manufacturing mammalian- and microbial-based therapeutics, vaccines, cell and gene therapies, and peptides.
  • Develop a strong understanding of the market, identify customer needs and challenges, and use Avantor’s portfolio of biopharma products and services to deliver solutions.
  • Conduct sales activities within the assigned territory, position Avantor as a preferred supplier, and drive profitable growth.
  • Maintain account relationships through customer-site visits; engage customers in person and via phone, chat, email, and video conferencing to support clients and close sales.
  • Respond to client inquiries and advise customers on appropriate products and services.
  • Execute sales strategy, generate sales reports, and identify opportunities to increase sales volume while meeting service levels.

About the company

Avantor provides high-purity lab chemicals, consumables, and related services to life sciences, healthcare, and advanced technologies worldwide. Its products support research, development, manufacturing, and quality control across discovery to delivery. The company differentiates itself through a broad, vertically integrated portfolio and the VWR acquisition, enabling customers to source materials and services in one place. Its goal is to be a trusted global partner that helps scientific progress by supplying essential materials and support across life sciences and tech workflows.

Company Size

10,001+

Company Stage

IPO

Headquarters

Bristol, Pennsylvania

Founded

1904

Get referred to Avantor

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $1.69 billion, and management raised 2026 guidance on July 29.
  • VWR returned to 1.7% organic growth in Q2 2026, ahead of schedule.
  • Todd Garner became CFO on September 21, 2026, sharpening financial discipline for deleveraging.

What critics are saying

  • In re Avantor securities litigation in Delaware targets VWR goodwill and competition disclosures.
  • Q2 2026 BMP revenue fell 5.6% organically, exposing fragile bioprocess demand.
  • Forty-nine employees were cut at Avantor Fluid Handling in July 2026, signaling ongoing restructuring.

What makes Avantor unique

  • Avantor owns VWR and NuSil, spanning distribution, silicones, and high-purity materials.
  • Avantor serves 300,000 customer locations across 180 countries, giving unmatched market reach.
  • Avantor's Revival program ties commercial, supply-chain, and e-commerce execution into one turnaround.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Holidays
  • Unlimited Paid Time Off
  • Paid Sick Leave

Company News

Yahoo Finance
Oct 27th, 2026
Avantor Q3 earnings preview: analysts expect 1.1% revenue growth after $1.69B last quarter

Avantor (NYSE:AVTR) will report third-quarter results on Wednesday before market open. Analysts expect revenue to grow 1.1% year on year, a reversal from the 5.3% decline in the same quarter last year. Last quarter, the life sciences company reported revenue of $1.69 billion, flat year on year, beating analyst estimates. It has missed Wall Street's revenue estimates multiple times over the last two years. Among peers, Thermo Fisher's revenue rose 9.1%, and Danaher's rose 8.3%. Thermo Fisher shares fell 1.6% after results, while Danaher's rose 2.4%. Avantor shares are up 11.8% over the last month and trade at $17.10. The average analyst price target is $15.50.

Yahoo Finance
Oct 26th, 2026
Avantor appoints Mikey Santiago, a four-time CIO, as chief information officer

Avantor, a life sciences and advanced technology supplier listed on the NYSE, has appointed Mikey Santiago as chief information officer. Santiago will lead the company's global IT strategy and its digital transformation, supporting growth, customer experience, and innovation. He brings more than two decades of technology experience, including four stints as a CIO and senior roles at Danaher Corporation and its operating companies. He has led digital transformations, acquisitions and integrations, cloud modernisation, cybersecurity, and AI projects. "Mikey brings an exceptional combination of business knowledge, technology leadership, and a proven ability to execute transformation at scale," said Emmanuel Ligner, president and chief executive officer of Avantor.

PR Newswire
Sep 21st, 2026
Avantor appoints new Chief Financial Officer.

Avantor appoints new Chief Financial Officer. Sep 21, 2026, 06:05 ET RADNOR, Pa., Sept. 21, 2026 /PRNewswire/ - Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, appoints Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026. Garner will oversee the company's global finance organization, including financial planning and analysis, accounting, treasury, tax, investor relations and internal audit. Emmanuel Ligner, Avantor President and CEO, says: "Todd is a proven financial leader with deep operational expertise, a strong track record of driving growth and extensive experience partnering with boards, investors and management teams. He brings the strategic mindset, financial discipline and leadership capabilities needed to support our next phase of growth and value creation. I am delighted to welcome Todd to Avantor and look forward to working together as we execute our strategy and continue serving our customers around the world." Todd Garner says: "Avantor plays a critical role in advancing some of the most important work in the life sciences and advanced technologies industries. I am excited to join the Company and look forward to working with colleagues and partners worldwide to build on Avantor's strong foundation and create long-term value for our customers and shareholders." Garner recently comes from CONMED Corporation, where he served as Executive Vice President and Chief Financial Officer from 2018-2026. He brings more than 30 years of finance, operational and public company leadership experience. Garner's previous experience includes a variety of leadership roles at C. R. Bard, Inc., including Vice President, Investor Relations and Division CFO, where he helped support significant shareholder value creation and business growth. Garner holds a bachelor of science in accounting from Brigham Young University, a master of business administration from the University of Texas Rio Grande Valley, and is a certified public accountant. Steve Eck, Senior Vice President and Chief Accounting Officer (CAO), has been serving as Interim CFO since June 24, 2026, and will continue in his CAO role. Ligner says: "Steve stepped up and led the finance organization with a steady hand and great commitment. We thank him for his leadership during the transition period and are pleased he'll continue in this valuable role as our CAO." About Avantor Avantor(R) is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook. SOURCE Avantor and Financial News

Yahoo Finance
Jul 29th, 2026
Avantor beats Q2 earnings estimates with $1.69B revenue, EPS surprise of 10.5%

Avantor reported second-quarter 2026 revenue of $1.69 billion, up 0.5% year-over-year, exceeding the consensus estimate of $1.62 billion by 4.17%. Earnings per share came in at $0.21, down from $0.24 in the prior-year quarter, but beating the $0.19 consensus estimate by 10.53%. The VWR Distribution & Services segment generated $1.24 billion in revenue, surpassing the $1.12 billion analyst estimate. The Bioscience & Medtech Products segment brought in $451.8 million, falling short of the $490.86 million estimate. Avantor shares have returned 25.5% over the past month, outpacing the S&P 500's 1.9% gain. The stock currently holds a Zacks Rank #2 (Buy).

Yahoo Finance
Jul 29th, 2026
Avantor beats Q2 estimates with $0.21 EPS and $1.69B revenue, shares up 8.4% YTD

Avantor reported second-quarter earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.19 per share by 10.53%. This represents a decline from $0.24 per share a year ago. The company has surpassed consensus earnings estimates three times over the last four quarters. Revenue reached $1.69 billion for the quarter ended June 2026, exceeding the Zacks Consensus Estimate by 4.17%. This compares to year-ago revenues of $1.68 billion. Avantor shares have added about 8.4% since the beginning of the year versus the S&P 500's gain of 8.5%. The stock currently holds a Zacks Rank of number 2 (Buy), suggesting it is expected to outperform the market in the near future.